<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Verapamil: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Verapamil: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Verapamil: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10043" href="/d/html/10043.html" rel="external">see "Verapamil: Drug information"</a> and <a class="drug drug_patient" data-topicid="11903" href="/d/html/11903.html" rel="external">see "Verapamil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F233861"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Calan SR [DSC];</li>
<li>Verelan;</li>
<li>Verelan PM</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868591"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Verap;</li>
<li>Isoptin SR;</li>
<li>MYLAN-Verapamil;</li>
<li>MYLAN-Verapamil SR;</li>
<li>PMS-Verapamil SR [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056017"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antianginal Agent</span>;</li>
<li>
<span class="list-set-name">Antiarrhythmic Agent, Class IV</span>;</li>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Calcium Channel Blocker</span>;</li>
<li>
<span class="list-set-name">Calcium Channel Blocker, Nondihydropyridine</span></li></ul></div>
<div class="block dop drugH1Div" id="F9729804"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f882e79-d62c-4b63-bf32-63cd49609f40">Supraventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supraventricular tachycardia (SVT):</b>
<b>Note:</b> Although verapamil is effective in the treatment of SVT, it is not included in the PALS tachyarrhythmia algorithm due to its adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: <b>Note:</b>
<b> May decrease cardiac output resulting in hypotension and possible cardiac arrest in infants; some experts consider verapamil use contraindicated</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>).<b> If used, it should only be with expert consultation and continuous ECG monitoring with IV calcium at the bedside:</b> 0.1 to 0.2 mg/kg/dose (usual: 0.75 to 2 mg/dose) may repeat dose after at least 30 minutes if response inadequate; optimal interval not defined; patient should be monitored closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.1','lexi-content-ref-Nelson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.1','lexi-content-ref-Nelson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents 1 to 15 years: 0.1 to 0.3 mg/kg/dose (usual dose: 2 to 5 mg/dose); maximum dose: 5 mg/dose; may repeat dose in 15 to 30 minutes if response inadequate; maximum dose for second dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-20956230','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-20956230','lexi-content-ref-Park.1'])">Ref</a></span>). <b>Note:</b> May also be administered intraosseous. Optimal interval for subsequent doses is unknown and must be individualized for each specific patient.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥16 years:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial dose:</p>
<p style="text-indent:-2em;margin-left:10em;">PALS guidelines: 0.1 to 0.3 mg/kg/dose; maximum dose: 5 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230','lexi-content-ref-Park.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Manufacturer's labeling: 5 to 10 mg (0.075 to 0.15 mg/kg/dose); maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8804320']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8804320'])">Ref</a></span>); similar dosing recommended in the adult ACC/AHA/HRS SVT guidelines: 5 to 10 mg (0.075 to 0.15 mg/kg) over 2 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Repeat dose: May repeat dose in 15 to 30 minutes if adequate response not achieved; maximum dose for second dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1','lexi-content-ref-20956230','lexi-content-ref-Park.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1','lexi-content-ref-20956230','lexi-content-ref-Park.1'])">Ref</a></span>). <b>Note:</b> Optimal interval for subsequent doses is unknown and must be individualized for each specific patient.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Limited data available: Children and Adolescents: Immediate release: 2 to 8 mg/kg/day in 3 divided doses; maximum daily dose: 480 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.1'])">Ref</a></span>). A mean daily dose of ~5 mg/kg/day (range: 2.3 to 8.1 mg/kg/day) was used in 22 children 15 days to 17 years of age receiving chronic oral therapy for SVT (n=20) or hypertrophic cardiomyopathy (n=2) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7725379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7725379'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51220284"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations. Based on experience in adult patients, use with caution and consider additional ECG monitoring; data suggest clearance of verapamil and its metabolite (norverapamil) is decreased; dosing adjustment suggested.</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis: Not removed by hemodialysis; supplemental dose is not necessary.</p></div>
<div class="block dohp drugH1Div" id="F51220285"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; based on in experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block doa drugH1Div" id="F233866"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10043" href="/d/html/10043.html" rel="external">see "Verapamil: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Avoid in patients taking a beta-blocker or who have heart failure with reduced ejection fraction, sinus node dysfunction, or second- or third-degree atrioventricular block unless a functioning pacemaker has been placed.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c263a8d4-f2ef-49a8-a963-6b87a475dbec">Angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic stable angina (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Alternative therapy if there are contraindications to or unacceptable adverse effects with beta-blockade (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: Initial: 80 to 120 mg 3 times daily; increase as needed at ≥1- to 2-day intervals to effective antianginal dose; maximum dose: 480 mg/day in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9174677','lexi-content-ref-Kannam.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9174677','lexi-content-ref-Kannam.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release: Initial: 180 mg once daily; increase as needed at 7- to 14-day intervals to effective antianginal dose; maximum dose: 480 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10073852','lexi-content-ref-Kannam.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10073852','lexi-content-ref-Kannam.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Vasospastic angina: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> May use alone or in combination with nitrates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: Initial: 80 to 120 mg 3 times daily; increase as needed at ≥1- to 2-day intervals to effective antianginal dose; maximum dose: 480 mg/day in 3 divided doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release: Initial: 180 mg once daily; increase as needed at 7- to 14-day intervals to effective antianginal dose; maximum dose: 480 mg/day in 1 to 2 divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0156d4e3-c53d-4d3c-809d-02d27775d840">Atrial fibrillation/flutter, rate control</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation/flutter, rate control (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For rate control in hemodynamically stable patients. Do <b>not</b> use in patients with preexcitation associated with an accessory pathway, as this can lead to ventricular arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347'])">Ref</a></span>). May be associated with more hypotension compared to diltiazem (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9399606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9399606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute ventricular rate control:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Bolus: Initial: 5 to 10 mg over ≥2 minutes; if there is inadequate response, dose may be repeated after 15 to 30 minutes; if there is adequate response after 1 to 2 bolus doses, then may begin a continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3757529','lexi-content-ref-Knight.1','lexi-content-ref-9399606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3757529','lexi-content-ref-Knight.1','lexi-content-ref-9399606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous infusion: Initial: 5 mg/hour; titrate to goal heart rate up to a maximum of 20 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-3757529','lexi-content-ref-Knight.1','lexi-content-ref-9399606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-3757529','lexi-content-ref-Knight.1','lexi-content-ref-9399606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic ventricular rate control:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: Initial: 40 mg 3 to 4 times daily; increase as needed to achieve rate control; maximum dose: 480 mg/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Knight.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Knight.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release (off-label use): Initial: 120 or 180 mg once daily; increase as needed to achieve rate control; maximum dose: 480 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-Knight.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-Knight.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86593b9d-77c8-4f4d-a837-9832f5bc0bd2">Chest pain associated with cocaine ingestion, with or without evidence of acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chest pain associated with cocaine ingestion, with or without evidence of acute coronary syndrome (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Adjunct or alternative agent in patients not controlled with nitroglycerin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Bolus: Initial: 2.5 to 5 mg over ≥2 minutes; may repeat after 15 minutes if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Morgan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Morgan.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59593e72-da61-44aa-a2f5-d8a3bbfdc680">Cluster headache, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cluster headache, prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as monotherapy or in combination with other preventive and/or bridging agents (eg, glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25911317','lexi-content-ref-33245858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25911317','lexi-content-ref-33245858'])">Ref</a></span>)). Example regimens are presented below. Obtain an ECG prior to treatment and after each titration when dose is &gt;480 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26868817']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26868817'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Initial: 40 to 80 mg 3 times daily; increase dose every 1 to 2 weeks until headaches subside or adverse reactions develop; usual effective dose: 240 to 480 mg/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2205598','lexi-content-ref-16987158','lexi-content-ref-26868817','lexi-content-ref-10746617','lexi-content-ref-25911317','lexi-content-ref-33245858','lexi-content-ref-31339562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2205598','lexi-content-ref-16987158','lexi-content-ref-26868817','lexi-content-ref-10746617','lexi-content-ref-25911317','lexi-content-ref-33245858','lexi-content-ref-31339562'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Initial: 240 mg in 2 divided doses; increase dose every 1 to 2 weeks until headaches subside or adverse reactions develop; usual effective dose: 240 to 480 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16987158','lexi-content-ref-2708046','lexi-content-ref-26868817','lexi-content-ref-25911317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16987158','lexi-content-ref-2708046','lexi-content-ref-26868817','lexi-content-ref-25911317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reserve nondihydropyridine calcium channel blockers for patients with a relevant comorbidity (eg, rate control in atrial fibrillation or flutter) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mann.1'])">Ref</a></span>). For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use in combination with another appropriate agent (eg, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Initial: 40 to 80 mg 3 times daily; increase dose as needed at weekly intervals; usual dose: 120 to 360 mg/day in 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>); maximum dose: 480 mg/day in 3 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Initial: 120 or 180 mg once daily; increase dose as needed at weekly intervals; usual dose: 120 to 360 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>); maximum dose: 480 mg/day in 1 to 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release (delayed-onset/PM formulation): Initial: 100 or 200 mg once daily at bedtime; increase dose as needed at weekly intervals; usual dose: 100 to 300 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>); maximum dose: 400 mg once daily at bedtime.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Note:</b> Tolerance may develop; consider increasing dose or switching to another calcium channel blocker if tolerance occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schwedt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schwedt.1'])">Ref</a></span>). An adequate trial for assessment of effect is considered to be at least 2 to 3 months at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Initial: 40 mg 3 times daily; titrate every 1 to 2 weeks based on patient response and tolerability up to 480 mg/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22683887','lexi-content-ref-Schwedt.1','lexi-content-ref-6355533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22683887','lexi-content-ref-Schwedt.1','lexi-content-ref-6355533'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: Initial: 120 mg once daily; titrate every 1 to 2 weeks based on patient response and tolerability up to 480 mg/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23203776','lexi-content-ref-10987906','lexi-content-ref-Schwedt.1','lexi-content-ref-12525732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23203776','lexi-content-ref-10987906','lexi-content-ref-Schwedt.1','lexi-content-ref-12525732'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f882e79-d62c-4b63-bf32-63cd49609f40">Supraventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, focal atrial tachycardia, multifocal atrial tachycardia) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For hemodynamically stable patients if vagal maneuvers and/or adenosine are unsuccessful. Do <b>not</b> use in patients with preexcitation associated with an accessory pathway, as this can lead to ventricular arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Bolus: Initial: 5 to 10 mg over ≥2 minutes; if response is insufficient after 15 to 30 minutes, a second bolus dose of 10 mg over 2 minutes may be administered. If 2 bolus doses do not terminate the arrhythmia, consider alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259','lexi-content-ref-20926952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259','lexi-content-ref-20926952'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic maintenance: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: Initial: 40 mg 3 to 4 times daily; increase as needed for heart rate control; maximum dose: 480 mg/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release (off-label use): Initial: 120 mg once daily; increase as needed for heart rate control; maximum dose: 480 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f42c553-e8c4-4b54-98fb-e270b999dc6b">Ventricular arrhythmias</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmias: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Idiopathic left ventricular tachycardia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In patients with wide QRS complex ventricular tachycardia of unknown origin, calcium channel blockers are potentially harmful. However, verapamil is safe and effective in patients with idiopathic left ventricular tachycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Acute idiopathic left ventricular tachycardia:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Bolus: 5 to 10 mg over ≥2 minutes; if no response after 15 to 30 minutes, may give 1 additional 10 mg bolus dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-Callans.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-Callans.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Prevention of idiopathic left ventricular arrhythmias:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Immediate release: 120 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1449923','lexi-content-ref-1279611','lexi-content-ref-8237755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1449923','lexi-content-ref-1279611','lexi-content-ref-8237755'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Extended release: 240 to 480 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>A beta-blocker is the preferred initial therapy; if there are ongoing symptoms on beta-blocker therapy, verapamil may be added with close monitoring of heart rate; verapamil may be used as an alternative therapy if beta-blockade cannot be tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29097320','lexi-content-ref-25172618','lexi-content-ref-Manolis.1','lexi-content-ref-Zimetbaum.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29097320','lexi-content-ref-25172618','lexi-content-ref-Manolis.1','lexi-content-ref-Zimetbaum.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Immediate release: Initial: 40 or 80 mg 3 times daily; titrate as needed based on symptom control and tolerability; maximum dose: 360 mg/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manolis.1','lexi-content-ref-Zimetbaum.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manolis.1','lexi-content-ref-Zimetbaum.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Extended release: Initial: 120 or 180 mg once daily; titrate as needed based on symptom control and tolerability; maximum dose: 360 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manolis.1','lexi-content-ref-Zimetbaum.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manolis.1','lexi-content-ref-Zimetbaum.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Conversion between oral formulations</b>: When switching from IR to ER formulations, the total daily dose remains the same unless formulation strength does not allow for equal conversion. At higher doses, some ER products are recommended to be given twice daily.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991192"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12589171','lexi-content-ref-2045528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12589171','lexi-content-ref-2045528'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2261942','lexi-content-ref-3230150','lexi-content-ref-4029246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2261942','lexi-content-ref-3230150','lexi-content-ref-4029246'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (highly protein bound, large V<sub>d</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12589171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12589171'])">Ref</a></span>)): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2261942','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2261942','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988271"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: In cirrhosis, reduce dose to 20% of normal and monitor ECG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7248141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7248141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Administer 30% of the normal dose in severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release (delayed-onset/PM formulation): Initial: 100 mg once daily at bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: There are no dosage adjustments provided in the manufacturer's labeling; use with caution and consider additional ECG monitoring in severe impairment. In cirrhosis, reduce dose to 50% of normal and monitor ECG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7248141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7248141'])">Ref</a></span>). Repeated injections in patients with hepatic failure may lead to accumulation. If repeated injections are essential, monitor BP and PR interval closely and use smaller doses.</p></div>
<div class="block arsc drugH1Div" id="F55808890"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute decompensated heart failure</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">In patients with left ventricular systolic dysfunction, use of verapamil may result in acute decompensation and deterioration with development of <b>pulmonary edema</b> and/or <b>hypotension</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3976695','lexi-content-ref-8376684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3976695','lexi-content-ref-8376684'])">Ref</a></span>). Acute <b>cardiac failure</b> associated with verapamil in patients with no prior history of chronic heart failure have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2915424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2915424'])">Ref</a></span>). Decompensated state should return to baseline after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2915424','lexi-content-ref-8339658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2915424','lexi-content-ref-8339658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Exhibits significant negative inotropic and vasodilator properties. Patients with left ventricular dysfunction may not be able to compensate or tolerate these hemodynamic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3976695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3976695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; typically within 4 to 5 days of therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2915424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2915424'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Severe left ventricular dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3976695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3976695'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2915424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2915424'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiac amyloidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8339658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8339658'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bradyarrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Verapamil may cause first-, second-, or third-degree <b>atrioventricular </b>(AV)<b> block</b> or sinus <b>bradycardia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15234417'])">Ref</a></span>). Although reversal is possible after discontinuation, some patients continue to have symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23878619','lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23878619','lexi-content-ref-15234417'])">Ref</a></span>). In patients whose symptoms resolve after discontinuation, permanent pacemaker (PPM) therapy will likely not be necessary; however, cases with recurrent or unresolved symptoms after discontinuation may warrant PPM placement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15234417'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Verapamil blocks L-type calcium channels, leading to prolonged refractoriness and slowing of conduction through the AV node (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6529866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6529866'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; in one study, bradycardia occurred 5 minutes after administration with a peak effect at 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6529866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6529866'])">Ref</a></span>). Other studies have suggested that conduction abnormalities may take a few weeks to develop (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17698788','lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17698788','lexi-content-ref-15234417'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use with other AV nodal-blocking agents (eg, beta-blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31788248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31788248'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Sick sinus syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-717239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-717239'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Underlying AV node dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15234417'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mild-to-moderate <b>increased serum transaminases</b>, <b>increased serum alkaline phosphatase</b>, and <b>increased serum bilirubin</b> have been reported, including self-limited <b>jaundice</b>. Complete recovery is generally expected within 2 to 4 weeks of discontinuation and may resolve with continuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6419928','lexi-content-ref-3953378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6419928','lexi-content-ref-3953378'])">Ref</a></span>). Rechallenge may result in rapid recurrence of hepatocellular injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7212507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7212507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; hypersensitivity or idiosyncratic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6419928','lexi-content-ref-3953378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6419928','lexi-content-ref-3953378'])">Ref</a></span>). Mechanism of hepatotoxicity is likely related to hypersensitivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7212507','lexi-content-ref-3953378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7212507','lexi-content-ref-3953378'])">Ref</a></span>). Verapamil is a derivative of papaverine, which is known to cause allergic hepatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7212507','lexi-content-ref-3953378','lexi-content-ref-6419928']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7212507','lexi-content-ref-3953378','lexi-content-ref-6419928'])">Ref</a></span>). The idiosyncratic cause may be due to mutations in efflux transport of verapamil (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28133614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28133614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; 2 to 6 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6419928','lexi-content-ref-3953378','lexi-content-ref-8048248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6419928','lexi-content-ref-3953378','lexi-content-ref-8048248'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F233823"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions presented are for the oral formation unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (IV, oral: 1% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:0em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (≤1%), angina pectoris (≤1%), ankle edema (1%), atrioventricular block (IV, oral: ≤1%), atrioventricular dissociation (≤1%), bradycardia (IV, oral: ≤1%), cardiac failure (≤2%), cerebrovascular accident (≤1%), chest pain (≤1%), claudication (≤1%), ECG abnormality (≤2%), edema (2%), hypotension (IV, oral: 2% to 3%, can be symptomatic), palpitations (≤1%), peripheral edema (4%)<span class="lexi-table-link-container"> (<a aria-label="Peripheral Edema table link" class="lexi-table-link" data-table-id="lexi-content-peripheral-edema" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-peripheral-edema')">table 1</a>)</span><span class="table-link" style="display:none;">Peripheral Edema</span>, syncope (≤1%), tachycardia (IV: 1%; severe)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Peripheral Edema" frame="border" id="lexi-content-peripheral-edema" rules="all">
<caption style="text-align:center;">
<b>Verapamil: Adverse Reaction: Peripheral Edema</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Verapamil)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Verapamil)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">All doses studied</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">297</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">116</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (≤1%), diaphoresis (IV, oral: ≤1%), ecchymoses (≤1%), erythema multiforme (≤1%), hyperkeratosis (≤1%), macular eruption (≤1%), skin rash (≤1%), Stevens-Johnson syndrome (≤1%), urticaria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Galactorrhea not associated with childbirth (≤1%), gynecomastia (≤1%), hyperprolactinemia (≤1%), spotty menstruation (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (4% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 2</a>)</span><span class="table-link" style="display:none;">Constipation</span>, diarrhea (≤1%), dyspepsia (3%), gastrointestinal distress (≤1%), gingival hyperplasia (≤1%), nausea (IV, oral: ≤3%), xerostomia (≤1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Verapamil: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Verapamil)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Verapamil)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">All doses studied</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">297</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">116</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediate release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">285</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4,954</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Extended release</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">200 mg/day</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (≤1%), purpuric vasculitis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Balance impairment (≤1%), confusion (≤1%), dizziness (IV, oral: 1% to 4%), drowsiness (IV, oral: ≤1%), extrapyramidal reaction (≤1%), fatigue (2%), insomnia (≤1%), lethargy (3%), paresthesia (≤1%), psychosis (≤1%), shakiness (≤1%), sleep disorder (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤1%), asthenia (≤2%), muscle cramps (≤1%), myalgia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (≤1%), flu-like symptoms (4%), pulmonary edema (≤2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Asystole, flushing, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, paralytic ileus (nonobstructive)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ventricular fibrillation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Psoriasis (Song 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (Hare 1986), increased serum bilirubin (Hare 1986), jaundice (Guarascio 1984)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (Dassylva 1993), seizure (during IV injection) (Maiteh 2001), vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle fatigue</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Rotary nystagmus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory failure (Zalman 1983)</p></div>
<div class="block coi drugH1Div" id="F233840"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Hypersensitivity to verapamil or any component of the formulation; severe left ventricular dysfunction; hypotension (systolic pressure &lt;90 mm Hg) or cardiogenic shock; sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker); second- or third-degree atrioventricular (AV) block (except in patients with a functioning artificial ventricular pacemaker); atrial flutter or fibrillation and an accessory pathway (Wolff-Parkinson-White [WPW] syndrome, Lown-Ganong-Levine syndrome).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Complicated myocardial infarction (MI) (ventricular failure manifested by pulmonary congestion); severe congestive heart failure and/or severe left ventricular dysfunction (eg, ejection fraction &lt;40%) unless secondary to a supraventricular tachycardia amendable to oral verapamil; marked bradycardia; concurrent use of ivabradine or flibanserin; concurrent use with beta-blockers in patients with poor ventricular function and in the treatment of hypertension; concurrent use of grapefruit juice; breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Hypersensitivity to verapamil or any component of the formulation; severe heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil); severe hypotension or cardiogenic shock; sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker); second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker); concurrent use of IV beta-blocking agents; atrial flutter or fibrillation and an accessory pathway (WPW syndrome, Lown-Ganong-Levine syndrome); ventricular tachycardia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Complicated MI (ventricular failure manifested by pulmonary congestion); severe left ventricular dysfunction; marked bradycardia; concurrent use of ivabradine or flibanserin; breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F233820"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Accessory pathway (eg, Wolff-Parkinson-White syndrome): During an episode of atrial fibrillation or flutter in patients with an accessory pathway or preexcitation syndrome, use has been associated with increased anterograde conduction down the accessory pathway leading to ventricular fibrillation; avoid use in such patients (ACLS [Neumar 2010]; AHA/ACC/HRS [January 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmia: Considered contraindicated in patients with wide complex tachycardias unless known to be supraventricular in origin; severe hypotension likely to occur upon administration (AHA [Panchal 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Attenuated neuromuscular transmission: Decreased neuromuscular transmission has been reported; use with caution in patients with attenuated neuromuscular transmission (Duchenne muscular dystrophy, myasthenia gravis); dosage reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reduction may be required; monitor hemodynamics and possibly ECG in severe impairment. Avoid repeated injections of IV verapamil in patients with significant hepatic failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intracranial pressure: IV verapamil has increased intracranial pressure in patients with supratentorial tumors at the time of anesthesia induction; use with caution in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Left ventricular dysfunction: Avoid use in patients with heart failure due to lack of benefit and/or worse outcomes with calcium channel blockers in general (AHA/ACC/HFSA [Heidenreich 2022]; AHA [Panchal 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; monitor hemodynamics and possibly ECG in severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: In neonates and young infants, avoid IV use for supraventricular tachycardia due to severe apnea, bradycardia, hypotensive reactions, and cardiac arrest; in older children, use IV with caution as myocardial depression and hypotension may occur (PALS [Kleinman 2010]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878669"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Although effective in terminating SVT in older children, verapamil is not the drug of choice (due to adverse effects) and is not included in the current PALS tachyarrhythmia algorithm.</p></div>
<div class="block dosfc drugH1Div" id="F56670926"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Some ER oral products may be referred to as sustained release in the manufacturer's labeling; however, there are generally no differences between products of the same dosage form described as ER or sustained release. All products are referred to as ER throughout the monograph.</p></div>
<div class="block foc drugH1Div" id="F233831"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Verelan: 120 mg, 180 mg [contains fd&amp;c red #40 (allura red ac dye), methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Verelan: 240 mg, 360 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Verelan PM: 100 mg, 200 mg, 300 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 120 mg, 180 mg, 200 mg, 240 mg, 300 mg, 360 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/mL (2 mL, 4 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/mL (2 mL, 4 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg, 80 mg, 120 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calan SR: 120 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calan SR: 180 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calan SR: 240 mg [DSC] [contains fd&amp;c blue #2 (indigo carm) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calan SR: 240 mg [DSC] [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 120 mg, 180 mg, 240 mg</p></div>
<div class="block geq drugH1Div" id="F233816"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F233842"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Verapamil HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $6.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $1.75 - $5.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $1.83 - $2.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $7.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $2.06 - $2.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $10.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $6.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Verelan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $7.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $8.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $9.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $13.35</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Verelan PM Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $6.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $8.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $11.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Verapamil HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/mL (per mL): $6.00 - $19.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Verapamil HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $1.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $1.44</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $1.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Verapamil HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $0.31 - $0.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $0.39 - $0.68</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868592"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 80 mg, 120 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isoptin SR: 120 mg, 180 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Isoptin SR: 240 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 120 mg, 180 mg, 240 mg</p></div>
<div class="block exp drugH1Div" id="F233838"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 50 mg/mL oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus or cherry syrup. When using cherry syrup, dilute cherry syrup concentrate 1:4 with simple syrup, NF. Crush seventy-five verapamil hydrochloride 80 mg tablets in a mortar and reduce to a fine powder. Add small portions of chosen vehicle (40 mL total) and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label "shake well", "refrigerate", and "protect from light". Stable for 60 days refrigerated (preferred) or at room temperature (Allen, 1996).</p>
<p style="text-indent:0em;margin-top:2em;">A 50 mg/mL oral suspension may be made with immediate release tablets, a 1:1 preparation of methylcellulose 1% and simple syrup, and purified water. Crush twenty 80 mg verapamil tablets in a mortar and reduce to a fine powder. Add 3 mL purified water USP and mix to a uniform paste; mix while adding the vehicle incremental proportions to <b>almost</b> 32 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 32 mL. Label "shake well" and  "refrigerate". Stable for 91 days refrigerated (preferred) or at room temperature (Nahata, 1997).</p>
<div class="reference">Allen LV Jr and Erickson MA 3rd, "Stability of Labetalol Hydrochloride, Metoprolol Tartrate, Verapamil Hydrochloride, and Spironolactone With Hydrochlorothiazide in Extemporaneously Compounded Oral Liquids," <i>Am J Health Syst Pharm</i>, 1996, 53(19):304-9.<span class="pubmed-id">8893069</span></div>
<div class="reference">Nahata MC, "Stability of Verapamil in an Extemporaneous Liquid Dosage Form," <i>J Appl Ther Res</i>, 1997,1(3):271-3.</div>
</div>
<div class="block admp drugH1Div" id="F52614005"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Immediate release: Can be administered with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Administer undiluted dose over 2 to 3 minutes; infuse over 3 to 4 minutes if blood pressure is in the lower range of normal</p></div>
<div class="block adm drugH1Div" id="F233836"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Do not crush or chew ER products.</p>
<p style="text-indent:-2em;margin-left:4em;">Calan SR, Isoptin SR (Canadian product): Administer with food. Isoptin SR 240 mg tablet may be split in half.</p>
<p style="text-indent:-2em;margin-left:4em;">Verelan, Verelan PM: Administer with or without food. Capsules may be opened and the contents sprinkled on 1 tablespoonful of applesauce, swallow immediately (without chewing) and follow with a glass of cool water. Do not subdivide contents of capsules.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER tablet should be swallowed whole. Do not crush or chew. IR tablet and injectable formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, selection of IR formulation or alternative therapy is advised for cardiovascular and other high-risk labeled and off-label indications.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer IV push over ≥2 minutes; in older patients for the acute treatment of supraventricular tachycardia, Advanced Cardiac Life Support guidelines recommend administering over 3 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Neumar.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Neumar.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F233854"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Calan, Calan SR: Store at 15°C to 25°C (59°F to 77°F). Protect from light and moisture.</p>
<p style="text-indent:-2em;margin-left:4em;">Verelan: Store at 20°C to 25°C (68°F to 77°F). Avoid excessive heat; protect from moisture. Brief temperature &gt;25°C (77°F) should be avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">Verelan PM: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59 to 86°F). Protect from moisture.</p></div>
<div class="block usep drugH1Div" id="F53569459"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of hypertension (all oral products) (FDA approved in adults); angina pectoris (vasospastic, chronic stable, unstable) (Calan, Covera-HS) (FDA approved in adults); supraventricular tachyarrhythmia [PSVT (prophylaxis), atrial fibrillation/flutter (rate control)] (Calan) (FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Supraventricular tachyarrhythmia [PSVT; atrial fibrillation/flutter (rate control)] (FDA approved in all ages)</p></div>
<div class="block mst drugH1Div" id="F233920"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Calan may be confused with Colace, dilTIAZem</p>
<p style="text-indent:2em;">Covera HS (DSC) may be confused with Covaryx HS</p>
<p style="text-indent:-2em;margin-left:4em;">Isoptin may be confused with Isopto Tears</p>
<p style="text-indent:-2em;margin-left:4em;">Verelan may be confused with Voltaren</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Verapamil, when used in infants &lt;1 year of age, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of asystole (weak recommendation; low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Dilacor [Brazil] may be confused with Dilacor XR brand name for dilTIAZem [US]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F233905"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak), CYP3A4 (moderate), P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F233825"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib.  Management: Monitor for increased abemaciclib toxicities if combined with moderate CYP3A4 inhibitors. Consider reducing the abemaciclib dose in 50 mg decrements if necessary.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALfentanil.  Management: If use of alfentanil and moderate CYP3A4 inhibitors is necessary, consider dosage reduction of alfentanil until stable drug effects are achieved. Frequently monitor patients for respiratory depression and sedation when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alfuzosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alitretinoin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALPRAZolam.  Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Calcium Channel Blockers (Nondihydropyridine) may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Astemizole.  Management: Avoid concomitant use of astemizole and moderate CYP3A4 inhibitors whenever possible. If combined, monitor closely for increased astemizole toxicities, especially for QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atogepant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: May increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of Atorvastatin. Management: Consider using lower doses of atorvastatin when used together with verapamil, and monitor closely for signs of HMG-CoA reductase inhibitor toxicity (eg, myositis, rhabdomyolysis, hepatotoxicity).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avacopan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor. Patients receiving such a combination should also be monitored more closely for evidence of adverse effects (eg, hypotension, syncope, priapism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avapritinib.  Management: Avoid use of moderate CYP3A4 inhibitors with avapritinib. If this combination cannot be avoided, reduce the avapritinib dose to 100 mg daily for the treatment of GIST or to 50 mg daily for the treatment of advanced systemic mastocytosis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Axitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bedaquiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Berotralstat.  Management: Decrease the berotralstat dose to 110 mg daily when combined with P-glycoprotein (P-gp) inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inhibitors when possible. If such a combination cannot be avoided, reduce the dose of brigatinib by approximately 40% (ie, from 180 mg to 120 mg, from 120 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor. The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic).  Management: Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and CYP3A4 inhibitors, they should be closely monitored for signs and symptoms of corticosteroid excess.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Capivasertib.  Management: If capivasertib is combined with moderate CYP3A4 inhibitors, reduce the capivasertib dose to 320 mg twice daily for 4 days, followed by 3 days off. Monitor patients closely for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine).  Management: Consider alternatives to this combination when possible. If combined, monitor for increased carbamazepine concentrations and toxicities and monitor for decreased calcium channel blocker efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cariprazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: Verapamil may enhance the bradycardic effect of Celiprolol. Verapamil may increase the serum concentration of Celiprolol.  Management: Concomitant use of verapamil and celiprolol is not recommended, particularly in patients with pre-existing conduction abnormalities. When switching from one agent to the other, a drug-free period is recommended, and heart rate should be monitored closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cisapride.  Management: Consider alternatives to this combination. Prescribing information for some moderate CYP3A4 inhibitors state coadministration with cisapride is contraindicated, while some others recommend monitoring and dose titration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid this combination when possible. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose from 60 mg to 20 mg daily. Avoid concomitant use in patients already receiving reduced cobimetinib doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Avoidance, dose reduction, or increased monitoring for colchicine toxicity may be needed and will depend on brand, indication for colchicine use, renal/hepatic function, and use of a P-gp inhibitor. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: This combination is often contraindicated, but combined use may be permitted with dose adjustment and monitoring. Recommendations vary based on brand, indication, use of CYP3A4 inhibitors, and hepatic/renal function. See interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Conivaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Conivaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Crizotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Verapamil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Verapamil. Management: Consider alternatives to this combination. If combined, monitor for reduced verapamil efficacy. Verapamil dose increases may be necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Verapamil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Verapamil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Daridorexant.  Management: Limit the daridorexant dose to 25 mg, no more than once per night, when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Darifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Delamanid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: Verapamil may enhance the adverse/toxic effect of Disopyramide. Of particular concern is the potential for profound depression of myocardial contractility.  Management: Concurrent use of disopyramide within 48 hours prior to or 24 hours after verapamil should be avoided.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Verapamil may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Dronedarone. Other electrophysiologic effects of Dronedarone may also be increased. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Dronedarone. Dronedarone may increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine).  Management: Use lower starting doses of the nondihydropyridine calcium channel blockers and only increase calcium channel blocker dose after obtaining ECG-based evidence that the combination is being well-tolerated. Monitor closely during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Verapamil may increase the serum concentration of Edoxaban.  Management: In patients treated for DVT/PE, reduce the edoxaban dose to 30 mg daily when combined with verapamil. No dose adjustment is recommended for patients treated for atrial fibrillation. Monitor for increased edoxaban toxicities (ie, bleeding) when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elbasvir and Grazoprevir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: When combined with moderate CYP3A4 inhibitors, elexacaftor/tezacaftor/ivacaftor should be given in the morning, every other day. Ivacaftor alone should be given in the morning, every other day on alternate days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce eliglustat dose to 84 mg daily in CYP2D6 EMs when used with moderate CYP3A4 inhibitors. Avoid use of moderate CYP3A4 inhibitors in CYP2D6 IMs or PMs. Use in CYP2D6 EMs or IMs also taking strong or moderate CYP2D6 inhibitors is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: Verapamil may increase the serum concentration of Encorafenib. Encorafenib may decrease the serum concentration of Verapamil.  Management: Avoid use of encorafenib and verapamil when possible. If combined, decrease the encorafenib dose from 450 mg to 225 mg; 300 mg to 150 mg; and 225 mg or 150 mg to 75 mg. Monitor for reduced verapamil efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Entrectinib.  Management: Avoid moderate CYP3A4 inhibitors if possible. If needed, reduce entrectinib dose to 50 mg/day if starting dose 200 mg; to 100 mg/day if starting dose 300 mg; to 200 mg if starting dose 400 mg or 600 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: If coadministered with moderate CYP3A4 inhibitors, the max dose of eplerenone is 25 mg daily if used for heart failure; if used for hypertension initiate eplerenone 25 mg daily, titrate to max 25 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Erythromycin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esmolol: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Esmolol.  Management: Administration of IV verapamil or diltiazem together with esmolol is contraindicated if one agent is given while the effects of the other are still present. Canadian esmolol labeling specifies that use within 24 hours is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Everolimus.  Management: Afinitor: For TSC-associated SEGA or TSC-associated seizures reduce everolimus dose 50%. For other Afinitor indications, reduce everolimus dose to 2.5 mg/day, increase to 5 mg/day if tolerated. Zortress: Monitor for increased everolimus concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fedratinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Consider fentanyl dose reductions when combined with a moderate CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: Verapamil may enhance the adverse/toxic effect of Flecainide. In particular, this combination may significantly impair myocardial contractility and AV nodal conduction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin.  Management: Use of flibanserin with moderate CYP3A4 inhibitors is contraindicated. If starting flibanserin, start 2 weeks after the last dose of the CYP3A4 inhibitor. If starting a CYP3A4 inhibitor, start 2 days after the last dose of flibanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Nasal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosaprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine).  Management: Consider alternatives to this combination when possible. If combined, monitor for increased phenytoin concentrations and toxicities and monitor for decreased calcium channel blocker efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Futibatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gepirone.  Management: Reduce the gepirone dose by 50% if combined with moderate CYP3A4 inhibitors. Monitor for QTc interval prolongation with combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gilteritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Glasdegib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Verapamil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the extended-release guanfacine dose 50% when combined with a moderate CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, the serum concentration of SN-38 may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Irinotecan Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Moderate) may increase isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions may be required; consult full drug interaction monograph content for age- and weight-specific dosage recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivosidenib.  Management: Avoid use of moderate CYP3A4 inhibitors with ivosidenib whenever possible. If combined, monitor for increased ivosidenib toxicities, including QTc prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin tablets with P-glycoprotein/ABCB1 inhibitors. If concomitant use is required, monitor for lefamulin adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Leniolisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levoketoconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomilnacipran: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomilnacipran. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Calcium Channel Blockers (Nondihydropyridine) may enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lopinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: Verapamil may increase the serum concentration of Lovastatin.  Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin, in patients receiving verapamil. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lumateperone.  Management: Limit the lumateperone dose to 21 mg once daily when used with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: US labeling recommends reducing lurasidone dose by 50% with a moderate CYP3A4 inhibitor and initiating 20 mg/day, max 80 mg/day. Some non-US labels recommend initiating lurasidone 20 mg/day, max 40 mg/day. Avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurbinectedin.  Management: Avoid concomitant use of lurbinectedin and moderate CYP3A4 inhibitors when possible. If combined, consider a lurbinectedin dose reduction as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Maraviroc. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Calcium Channel Blockers (Nondihydropyridine) may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a non-DHP CCB. For those stable on mavacamten who are initiating a non-DHP CCB, reduce mavacamten dose by one dose level. Monitor for excessive negative inotropic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: Verapamil may diminish the therapeutic effect of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methadone.  Management: If coadministration with moderate CYP3A4 inhibitors is necessary, consider methadone dose reductions until stable effects are achieved. Monitor patients closely for respiratory depression and sedation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midazolam.  Management: Avoid concomitant use of nasal midazolam and moderate CYP3A4 inhibitors. Consider alternatives to use with oral midazolam whenever possible and consider using lower midazolam doses. Monitor patients for sedation and respiratory depression if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midostaurin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MiFEPRIStone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mitapivat.  Management: When coadministered with moderate CYP3A4 inhibitors, doses of mitapivat should not exceed 20 mg twice daily. Additionally, patients should be monitored for changes in hemoglobin response and increased mitapivat adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mobocertinib.  Management: Avoid use of moderate CYP3A4 inhibitors with mobocertinib when possible. If combined, the mobocertinib dose should be reduced by approximately 50% (ie, from 160 mg to 80 mg, 120 mg to 40 mg, or 80 mg to 40 mg). Monitor QTc interval closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Nadolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol.  Management: The use of naloxegol and moderate CYP3A4 inhibitors should be avoided. If concurrent use is unavoidable, reduce naloxegol dose to 12.5 mg once daily and monitor for signs of opiate withdrawal (eg, hyperhidrosis, chills, diarrhea, anxiety, irritability).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nilotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 150 mg twice daily and the dose of olaparib capsules should be reduced to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Omaveloxolone.  Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 100 mg daily and monitor closely for adverse reactions. If adverse reactions occur, decrease omaveloxolone to 50 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palovarotene.  Management: Avoid concomitant use of palovarotene and moderate CYP3A4 inhibitors when possible. If combined, decrease palovarotene dose by 50% as described in the full interaction monograph. Monitor for palovarotene toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Panobinostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pemigatinib.  Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the moderate inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pexidartinib.  Management: If combined use cannot be avoided, pexidartinib dose should be reduced. For the 125 mg capsules: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily. Reduce pexidartinib 250 mg daily to 125 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimavanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pirtobrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: Verapamil may enhance the hypotensive effect of Pramipexole. Verapamil may increase the serum concentration of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazepam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Prazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Quinidine (Non-Therapeutic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors. Monitor for increased ranolazine effects and toxicities during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin (and possibly other related compounds) may be increased.  Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix.  Management: Avoid coadministration of relugolix with oral P-gp inhibitors whenever possible. If combined, take relugolix at least 6 hours prior to the P-gp inhibitor and monitor patients more frequently for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Relugolix, Estradiol, and Norethindrone.  Management: Avoid use of relugolix/estradiol/norethindrone with P-glycoprotein (P-gp) inhibitors. If concomitant use is unavoidable, relugolix/estradiol/norethindrone should be administered at least 6 hours before the P-gp inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ribociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rimegepant.  Management: If taking rimegepant for the acute treatment of migraine, avoid a second dose of rimegepant within 48 hours when used concomitantly with moderate CYP3A4 inhibitors. No dose adjustment needed if using rimegepant for prevention of episodic migraine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rimegepant.  Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Inhibitors of CYP3A4 (Moderate) and P-glycoprotein may increase the serum concentration of Rivaroxaban.  Management: No action is needed in patients with normal renal function. Do not use this combination in patients with estimated creatinine clearance 15 to 80 mL/min unless prospective benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RomiDEPsin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selpercatinib.  Management: Avoid combination if possible. If use is necessary, reduce selpercatinib dose as follows: from 120 mg twice/day to 80 mg twice/day, or from 160 mg twice/day to 120 mg twice/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selumetinib.  Management: Avoid concomitant use when possible. If combined, selumetinib dose reductions are recommended and vary based on body surface area and selumetinib dose. For details, see the full drug interaction monograph or selumetinib prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: Verapamil may increase serum concentrations of the active metabolite(s) of Simvastatin. Verapamil may increase the serum concentration of Simvastatin.  Management: Carefully consider the potential risks and benefits of this combination. If coadministered, limit adult simvastatin dose to 10 mg daily, and monitor closely for signs of simvastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Conventional).  Management: Monitor for increased serum concentrations of sirolimus if combined with a moderate CYP3A4 inhibitor. Lower initial sirolimus doses or sirolimus dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Conventional).  Management: Avoid concurrent use of sirolimus with P-glycoprotein (P-gp) inhibitors when possible and alternative agents with lesser interaction potential with sirolimus should be considered. Monitor for increased sirolimus concentrations/toxicity if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.  Management: The recommended dose of suvorexant is 5 mg daily in patients receiving a moderate CYP3A4 inhibitor. The dose can be increased to 10 mg daily (maximum dose) if necessary for efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: Verapamil may increase the serum concentration of Talazoparib.  Management: In breast cancer, if concurrent use cannot be avoided, reduce talazoparib dose to 0.75 mg once daily. In prostate cancer, monitor patients for increased adverse events.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tazemetostat.  Management: Avoid when possible. If combined, reduce tazemetostat dose from 800 mg twice daily to 400 mg twice daily, from 600 mg twice daily to 400 mg in AM and 200 mg in PM, or from 400 mg twice daily to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tegaserod (Withdrawn from US Market): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tegaserod (Withdrawn from US Market). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Disoproxil Fumarate: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Terfenadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor and Ivacaftor.  Management: If combined with moderate CYP3A4 inhibitors, give tezacaftor/ivacaftor in the morning, every other day; give ivacaftor in the morning, every other day on alternate days. Tezacaftor/ivacaftor dose depends on age and weight; see full Lexi-Interact monograph<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Verapamil may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.  Management: Avoid this combination with Samsca brand of tolvaptan. Reduce dose for Jynarque brand: 90 mg AM and 30 mg PM, reduce to 45 mg AM and 15 mg PM; 60 mg AM and 30 mg PM, reduce to 30 mg AM and 15 mg PM; 45 mg AM and 15 mg PM, reduce to 15 mg AM and PM.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of TraMADol. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Triazolam.  Management: Consider triazolam dose reduction in patients receiving concomitant moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and avoid a second dose for 24 hours when used with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vamorolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vamorolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vardenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vardenafil.  Management: Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined with moderate CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and moderate CYP3A4 inhibitors. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with moderate CYP3A4 inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinBLAStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinBLAStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Vinflunine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vinflunine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Voclosporin.  Management: Decrease the voclosporin dose to 15.8 mg in the morning and 7.9 mg in the evening when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vorapaxar. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zanubrutinib.  Management: Decrease the zanubrutinib dose to 80 mg twice daily during coadministration with a moderate CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuranolone. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F233856"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Ethanol: Verapamil may increase blood ethanol levels and prolong its effects. Management: Monitor patients and caution about increased effects.</p>
<p style="text-indent:-2em;margin-left:2em;">Food: Grapefruit juice may increase the serum concentration of verapamil. Management: Use with caution and monitor for effects.</p></div>
<div class="block rep_considerations drugH1Div" id="F58031972"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Verapamil is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Verapamil may be effective for prevention of migraines. In general, preventive treatment for migraine in patients trying to become pregnant should be avoided. Options for patients planning a pregnancy should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data and needs of the patient should pregnancy occur. A gradual discontinuation of preventive medications is generally preferred when the decision is made to stop treatment prior to conception (ACOG 2022; AHS [Ailani 2021]).</p></div>
<div class="block pri drugH1Div" id="F233843"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Verapamil crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of hypertension is initiated during pregnancy, agents other than verapamil may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with hypertrophic cardiomyopathy who are controlled with verapamil prior to pregnancy may continue therapy, but increased fetal monitoring is recommended (AHA/ACC [Ommen 2020]). Verapamil may be used IV for the acute treatment of supraventricular tachycardia (SVT) in patients who are pregnant when adenosine or beta-blockers are ineffective or contraindicated. Verapamil may also be used for the ongoing management of SVT in highly symptomatic patients. The lowest effective dose is recommended; avoid use during the first trimester if possible (ACC/AHA/HRS [Page 2016]). Additional guidelines are available for management of cardiovascular diseases during pregnancy (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">In general, preventive treatment for migraine should be avoided during pregnancy. Options for pregnant patients should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data, the potential for adverse maternal and fetal events, and needs of the patient (ACOG 2022; AHS [Ailani 2021]). If preventive therapy is needed, verapamil may be used (ACOG 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Verapamil is used for the prevention of cluster headache (AHS [Robbins 2016]). Verapamil may be used when prophylaxis is needed in pregnant patients; however, use should be avoided during the third trimester if possible (Bjørk 2021).</p></div>
<div class="block mopp drugH1Div" id="F53569458"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor blood pressure and heart rate; periodic liver function tests; ECG, especially with renal and/or hepatic impairment</p>
<p style="text-indent:0em;margin-top:2em;">Consult individual institutional policies and procedures.</p></div>
<div class="block pha drugH1Div" id="F233819"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits calcium ion from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina; slows automaticity and conduction of AV node.</p></div>
<div class="block phk drugH1Div" id="F233839"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Lean body weight affects verapamil pharmacokinetics inversely.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Peak effect: Oral: Immediate release: 1 to 2 hours (Singh 1978); IV bolus: 3 to 5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral: Immediate release: 6 to 8 hours; IV: 0.5 to 6 hours (Marik 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed (&gt;90%).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3.89 L/kg (Storstein 1984).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (extensive first-pass effect) via multiple CYP isoenzymes; primary metabolite is norverapamil (~20% pharmacologic activity of verapamil).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 20% to 35%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Injection: Terminal: 2 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: Single dose: 2.8 to 7.4 hours; Multiple doses: 4.5 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: ~12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe hepatic impairment: 14 to 16 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: 1 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release:</p>
<p style="text-indent:-2em;margin-left:6em;">Calan SR: 5.21 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Verelan: 7 to 9 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Verelan PM: ~11 hours; Drug release delayed ~4 to 5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~70% as metabolites, 3% to 4% as unchanged drug); feces (≥16%).</p></div>
<div class="block phksp drugH1Div" id="F51204426"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Metabolism is delayed, half-life is prolonged, volume of distribution is increased, and plasma clearance is reduced to ~30% of normal.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Elimination half-life may be prolonged and bioavailability may be higher in older adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Conflicting data suggest that verapamil clearance decreased with age in females to a greater degree than in males.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F233846"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cardiagutt | Flamon | Isoptin | Verpamil</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dramion | Isoptino | Verahexal rr | Veral</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Isoptin retard | Verapabene | Verapamil | Verastad</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Anpec | Cordilox | Isoptin | Veracap | Verahexal</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Akilen | Angimil | Calan | Danistole | Vasodil | Veracal | Veramil</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Isoptine | Lodixal</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Angigo | Vera denk</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Isocor | Isoptin | Lekoptin | Verapamil | Verapamil Sopharma | Verogalid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de verapamil | Cordilat | Cronovera | Dilacard | Dilacor | Dilacoron | Multicor | Neo verpamil | Vascord | Vasoton | Veracoron | Veralpress | Veramil | Verapamila | Verapress | Veraval</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Flamon | Isoptin | Verapam | Verapamil UPSA</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cardiolen | Isoptina | Presocor</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao di mai er | Gai heng | Isoptin | Novopressan | Nuo fu sheng | Verapamil</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Suipamil | Vasomed | Venture | Verapamil | Verapamil mk | Verapamilo | Verapax | Veratad | Veratril | Verax | Zosincol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Berkatens | Isocor | Isoptin | Isoptin ichs | Isoptin sr | Lekoptin | Verahexal | Verahexal khk | Verahexal rr | Verapamil | Verapamil al | Verogalid | Verpamil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aventurin | Azupamil | Cardioprotect | Dignover | Durasoptin | Falicard | Half Securon | Isoptin | Isoptine | Jenapamil | Vera | Vera 1 A Pharma | Vera biochemie | Vera Heumann | Vera lich | Verabeta | Veradurat | Veragamma | Verahexal | Verahexal khk | Verahexal rr | Veramex | Veranorm | Verapamil | Verapamil 1 A Pharm | Verapamil 3mm | Verapamil al | Verapamil Carino | Verapamil denk | Verapamil Dura | Verapamil R | Verapamil sandoz | Verapamil teva | Verapamil Verla | Verasal | Veroptinstada</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Antagocal | Coragina | Isoptin | Lufrapamil | Pamicol | Suipamil | Verabloc | Verapamil | Verapamilo | Verapil | Veratad | Verdilac</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Librapamil | Niposoluted | Raserpamil | Verapamil mk | Verapamilo | Veratad</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Falicard | Geangin | Isoptin | Lekoptin | Manidon | Verahexal | Verakard | Verapamil | Verapamil hennig | Verapamil ozon | Verapamil ratiopharm | Verogalid | Verpamil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cardiomil | Globamil | Glopamil | Isoptin | Izoptomil | Veratens | Verpamil</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Manidon | Manidon hta | Veratensin hta</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Aventurin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Calcimil | Geangin | Hexasoptin | Isoptin | Veracal | Vermin | Verpacor | Verpamil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Arpamyl | Isoptine | Verapamil | Verapamil Biogaran | Verapamil Dakota | Verapamil Dci | Verapamil G Gam | Verapamil gnr | Verapamil ivax | Verapamil merck | Verapamil mylan pharma | Verapamil ratiopharm | Verapamil sandoz | Verapamil teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Berkatens | Cordilox | Dumopamil | Ethimil | Geangin | Ranvera | Securon | Univer | Vera til sr | Veradur mr | Verapamil | Verapamil Abbott | Verapamil aps | Verapamil arrow | Verapamil berk | Verapamil cox | Verapamil dc | Verapamil kent | Verapamil sandoz | Verapress | Verapress cox | Verapress mr | Veratil | Vertab</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Verapamil hydrochloride&amp;Ratiopharm</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Akilen | Apo-verap | Cintsu | Civicor | Isoptin | Vasomil | Verapamil | Verapamil HCL | Verpamil</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Isoptin rr</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Chinopamil r | Isoptin | Verapamil | Verapamil al | Verogalid | Verpamil</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cardiover | Corpamil | Isoptin | Verapamil</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Berkatens | Isoptin | Securon | Veramil | Verap | Verelan | Verisop</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ikacor | Ikapress | Veracor | Verapress</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Calaptin | Vpl</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cardinorm | Isoptin | Isoptin press | Kata | Quasar | Verapamil | Verapamil eg | Verapamil Hex | Veraptin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Isoptin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Hormitol | Magotiron | Rabatelan | Rabatelan taiyo | Rositol | Vasolan | Verapamil HCL</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Isoptin sr | Vera denk</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cordilox | Isoptin | Veramil | Verapamil | Verelan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Flamon | Isoptin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo verap sr | Fibrocard | Flamon | Isoptin | Verapamil</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Akilen | Falicard | Finoptin | Isoptin | Lekoptin | Staveran | Veragamma | Veramil | Verapamil | Verogalid | Verpamil</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Isoptin khk | Verahexal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Falicard | Finoptin | Flamon | Geangin | Isoptin | Lekoptin | Securon | Staveran | Veragamma | Verahexal | Verakard | Veramil | Verapamil | Verapamil al | Verogalid | Verpamil</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Fibrocard</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Apo-mile | Cronovera | Dilacoran | Dilacoran retard | Euritmin | Palyuan | Quimil | Velpitax | Venipres | Vepiltax | Veraken | Verapamilo | Verapamilo landsteiner | Verapamilo mavi | Verapamilo nafar | Vicari</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Akilen | Anpec | Isoptin | Isoptin sr | Verahexal | Verapamil | Verapamil Pharmaniaga | Verpamil | Viratin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Geangin | Isoptin | Isoptin sr | Isoptine | Verapamil | Verapamil HCL | Verapamil HCl A | Verapamil HCl Katwijk | Verapamil hcl ratiopharm | Verapamil hcl-gf | Vortac</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Isoptin khk | Isoptin mite | Isoptin nordic prime | Verahexal | Verakard | Veraloc | Verapamil | Verapamil retard</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Verapamil | Verpamil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Verapamil Hydrochloirde | Verapamilo</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Calan | Isoptin | Veral | Veramet | Verapamil sandoz | Verelan</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Calan | Isocardin | Isoptin | Verapamil | Zavera</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo-verap | Isoptin | Lekoptin | Novo-veramil | Staveran | Verapamil | Veratio | Verpamil</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Calan | Covera-Hs | Isoptin | Verapamil | Verapamil HCL | Verapamil Hydrochloirde | Verelan | Verelan PM</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Verapamil</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Isoptino | Isoptino retard | Isoptino sr | Verapamilo dutriec | Verapamilo genfar</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Isoptin SR | Securon IV</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cordamil | Isoptin | Isoptin rr | Verahexal | Verapamil | Verapamil al | Verapamil arena | Verapamil sanofi | Verazil | Verogalid | Verpamil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Caveril | Falicard | Finoptin | Isoptin | Lekoptin | Veracard | Veramil | Verapamil | Verapamil (mival) | Verapamil escom | Verapamil ferein | Verapamil lekt | Verapamil ratiopharm | Verapamil Sopharma | Verapamil-mik | Vero verapamil | Verogalid | Veromil</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-verap | Caveril | Isoptin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cavartil | Isoptin | Isoptin retard | Veraloc | Verapamil Merck NM | Verapamil mylan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Verapamil | Verpamil</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Lekoptin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Lekoptin | Verahexal | Verahexal khk | Verahexal rr | Verapamil | Verapamil al | Verogalid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cardimed | Caveril | Isola | Isopamil | Isoptin | Sopmil | Vasopten | Verapamil | Verapin | Vermine | Verpacin | Zyrane</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Isoptine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Isopamil | Isoptin | Isoptin KKH | Ormil | Veramil | Veroptin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anpec | Cardiagutt | Cintsu | Isomil | Isonine | Isoperdine | Isoptin | Napamil | Singen | Sinrox | U Sodin | Verapam | Verapamil | Verelan | Verpamil | Vetrimil</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Falicard | Finoptin | Isoptin | Isoptin sr | Lekoptin | Verapamil | Verapamil darnitsa | Veratard | Verogalid</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Coridamol | Isoptino | Veralien | Verapamil</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cronovera-hs | Manidon | Pamiwell | Veracor | Verapamil | Verapamilo</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Calcicard sr | Isoptin | Ravamil | Ravamil SR | Rolab-verapamil | Vasomil | Verahexal | Verapamil | Verapamil sandoz</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Vera denk | Verapamil</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Isoptin | Vasomil | Verahexal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. Published online October 30, 2017. doi:10.1161/CIR.0000000000000549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29097320">
<a name="29097320"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2018;15(10):e190-e252. doi:10.1016/j.hrthm.2017.10.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/29097320/pubmed" id="29097320" target="_blank">29097320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee on clinical practice guidelines–obstetrics. Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628513">
<a name="6628513"></a>Andersen HJ. Excretion of verapamil in human milk. <i>Eur J Clin Pharmacol</i>. 1983;25(2):279-280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/6628513/pubmed" id="6628513" target="_blank">6628513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3830249">
<a name="3830249"></a>Anderson P, Bondesson U, Mattiasson I, Johansson BW. Verapamil and norverapamil in plasma and breast milk during breast feeding. <i>Eur J Clin Pharmacol</i>. 1987;31(5):625-627.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/3830249/pubmed" id="3830249" target="_blank">3830249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apo-Verap.1">
<a name="Apo-Verap.1"></a>Apo-Verap (verapamil) [product monograph]. Weston, Ontario, Canada: Apotex; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation.</i> 2011;123(21):2434-2506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3757529">
<a name="3757529"></a>Barbarash RA, Bauman JL, Lukazewski AA, Srebro JP, Rich S. Verapamil infusions in the treatment of atrial tachyarrhythmias. <i>Crit Care Med</i>. 1986;14(10):886-888.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/3757529/pubmed" id="3757529" target="_blank">3757529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2261942">
<a name="2261942"></a>Beyerlein C, Csaszar G, Hollmann M, Schumacher A. Verapamil in antihypertensive treatment of patients on renal replacement therapy--clinical implications and pharmacokinetics. <i>Eur J Clin Pharmacol.</i> 1990;39(suppl 1):S35-S37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/2261942/pubmed" id="2261942" target="_blank">2261942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33852763">
<a name="33852763"></a>Bjørk MH, Kristoffersen ES, Tronvik E, Egeland Nordeng HM. Management of cluster headache and other trigeminal autonomic cephalalgias in pregnancy and breastfeeding. <i>Eur J Neurol</i>. 2021;28(7):2443-2455. doi:10.1111/ene.14864<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/33852763/pubmed" id="33852763" target="_blank">33852763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12383588">
<a name="12383588"></a>Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). <i>J Am Coll Cardiol.</i> 2002;40(7):1366-1374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/12383588/pubmed" id="12383588" target="_blank">12383588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7212507">
<a name="7212507"></a>Brodsky SJ, Cutler SS, Weiner DA, Klein MD. Hepatotoxicity due to treatment with verapamil. <i>Ann Intern Med</i>. 1981;94(4 pt 1):490-491. doi:10.7326/0003-4819-94-4-490<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/7212507/pubmed" id="7212507" target="_blank">7212507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2205598">
<a name="2205598"></a>Bussone G, Leone M, Peccarisi C, et al. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. <i>Headache</i>. 1990;30(7):411-417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/2205598/pubmed" id="2205598" target="_blank">2205598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Calan.1">
<a name="Calan.1"></a>Calan (verapamil) [prescribing information]. New York, NY: Pfizer; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CalanIR.1">
<a name="CalanIR.1"></a>Calan IR (verapamil) [prescribing information]. New York, NY: Pfizer; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CalanSR.1">
<a name="CalanSR.1"></a>Calan SR (verapamil) extended-release tablets [prescribing information]. New York, NY: Pfizer; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Callans.1">
<a name="Callans.1"></a>Callans DJ. Ventricular tachycardia in the absence of apparent structural heart disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-717239">
<a name="717239"></a>Carrasco HA, Fuenmayor A, Barboza JS, Gonzalez G. Effect of verapamil on normal sinoatrial node function and on sick sinus syndrome. <i>Am Heart J</i>. 1978;96(6):760-771. doi:10.1016/0002-8703(78)90009-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/717239/pubmed" id="717239" target="_blank">717239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9737655">
<a name="9737655"></a>Chow T, Galvin J, McGovern B. Antiarrhythmic drug therapy in pregnancy and lactation. <i>Am J Cardiol.</i> 1998;82(4A):58I-62I.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/9737655/pubmed" id="9737655" target="_blank">9737655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17698788">
<a name="17698788"></a>Cohen AS, Matharu MS, Goadsby PJ. Electrocardiographic abnormalities in patients with cluster headache on verapamil therapy. <i>Neurology</i>. 2007;69(7):668-675. doi:10.1212/01.wnl.0000267319.18123.d3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/17698788/pubmed" id="17698788" target="_blank">17698788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3976695">
<a name="3976695"></a>Colucci WS, Fifer MA, Lorell BH, Wynne J. Calcium channel blockers in congestive heart failure: theoretic considerations and clinical experience. <i>Am J Med</i>. 1985;78(2B):9-17. doi:10.1016/0002-9343(85)90164-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/3976695/pubmed" id="3976695" target="_blank">3976695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CoveraHS.1">
<a name="CoveraHS.1"></a>Covera-HS (verapamil) [prescribing information]. New York, NY: Pfizer; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8518988">
<a name="8518988"></a>Dassylva B. Verapamil may cause depression. <i>Can J Psychiatry</i>. 1993;38(4):299-300. doi:10.1177/070674379303800420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/8518988/pubmed" id="8518988" target="_blank">8518988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20926952">
<a name="20926952"></a>Delaney B, Loy J, Kelly AM. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. <i>Eur J Emerg Med</i>. 2011;18(3):148-152. doi:10.1097/MEJ.0b013e3283400ba2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/20926952/pubmed" id="20926952" target="_blank">20926952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8376684">
<a name="8376684"></a>Elkayam U, Shotan A, Mehra A, Ostrzega E. Calcium channel blockers in heart failure. <i>J Am Coll Cardiol</i>. 1993;22(4 suppl A):139A-144A. doi:10.1016/0735-1097(93)90478-j<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/8376684/pubmed" id="8376684" target="_blank">8376684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation.</i> 2010;122 (18 suppl 3):640-656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [published correction appears in <i>Circulation. </i>2014;129(16):e463]. <i>Circulation.</i> 2012;126(25):3097-3137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3378854">
<a name="3378854"></a>Finucci GF, Padrini R, Piovan D, et al. Verapamil pharmacokinetics and liver function in patients with cirrhosis. <i>Int J Clin Pharmacol Res</i>. 1988;8(2):123-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/3378854/pubmed" id="3378854" target="_blank">3378854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10073852">
<a name="10073852"></a>Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi TD. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris.<i> Am J Cardiol</i>. 1999;83(4):507-514.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/10073852/pubmed" id="10073852" target="_blank">10073852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2708046">
<a name="2708046"></a>Gabai IJ, Spierings EL. Prophylactic treatment of cluster headache with verapamil. <i>Headache</i>. 1989;29(3):167-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/2708046/pubmed" id="2708046" target="_blank">2708046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.1">
<a name="Gal.1"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19561715">
<a name="19561715"></a>Garmel GM. Wide Complex Tachycardias: Understanding this complex condition part 2 - Management, miscellaneous causes, and pitfalls. <i>West J Emerg Med</i>. 2008;9(2):97-103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/19561715/pubmed" id="19561715" target="_blank">19561715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8237755">
<a name="8237755"></a>Gill JS, Blaszyk K, Ward DE, Camm AJ. Verapamil for the suppression of idiopathic ventricular tachycardia of left bundle branch block-like morphology. <i>Am Heart J</i>. 1993;126(5):1126-1133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/8237755/pubmed" id="8237755" target="_blank">8237755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1449923">
<a name="1449923"></a>Gill JS, Mehta D, Ward DE, Camm AJ. Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. <i>Br Heart J.</i> 1992a;68(4):392-397.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/1449923/pubmed" id="1449923" target="_blank">1449923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1279611">
<a name="1279611"></a>Gill JS, Ward DE, Camm JA. Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. <i>Pacing Clin Electrophysiol.</i> 1992b;15(11, pt 2):2122-2126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/1279611/pubmed" id="1279611" target="_blank">1279611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6419928">
<a name="6419928"></a>Guarascio P, D'Amato C, Sette P, Conte A, Visco G. Liver damage from verapamil. <i>Br Med J</i>. 1984;288(6414):362-363.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/6419928/pubmed" id="6419928" target="_blank">6419928</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3230150">
<a name="3230150"></a>Hanyok JJ, Chow MS, Kluger J, Izard MW. An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients. <i>J Clin Pharmacol.</i> 1988;28(9):831-836. doi:10.1002/j.1552-4604.1988.tb03224.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/3230150/pubmed" id="3230150" target="_blank">3230150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3953378">
<a name="3953378"></a>Hare DL, Horowitz JD. Verapamil hepatotoxicity: a hypersensitivity reaction. <i>Am Heart J</i>. 1986;111(3):610-611. doi:10.1016/0002-8703(86)90078-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/3953378/pubmed" id="3953378" target="_blank">3953378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9174677">
<a name="9174677"></a>Hauf-Zachariou U, Blackwood RA, Gunawardena KA, O'Donnell JG, Garnham S, Pfarr E. Carvedilol versus verapamil in chronic stable angina: a multicentre trial.<i> Eur J Clin Pharmacol</i>. 1997;52(2):95-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/9174677/pubmed" id="9174677" target="_blank">9174677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6468488">
<a name="6468488"></a>Inoue H, Unno N, Ou MC, Iwama Y, Sugimoto T. Level of verapamil in human milk. <i>Eur J Clin Pharmacol</i>. 1984;26(5):657-658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/6468488/pubmed" id="6468488" target="_blank">6468488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IsoptinSR.1">
<a name="IsoptinSR.1"></a>Isoptin SR (verapamil) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30703530">
<a name="30703530"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.<i> Heart Rhythm</i>. 2019:S1547-5271(19)30037-2. doi:10.1016/j.hrthm.2019.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/30703530/pubmed" id="30703530" target="_blank">30703530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kannam.1">
<a name="Kannam.1"></a>Kannam JP, Gersh BJ. Calcium channel blockers in the management of stable angina pectoris. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 20, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Knight.1">
<a name="Knight.1"></a>Kaplan R. Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6529866">
<a name="6529866"></a>Klein GJ, Twum-Barima Y, Gulamhusein S, Carruthers SG, Donner AP. Verapamil in chronic atrial fibrillation: variable patterns of response in ventricular rate. <i>Clin Cardiol</i>. 1984;7(9):474-483. doi:10.1002/clc.4960070903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/6529866/pubmed" id="6529866" target="_blank">6529866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation. </i>2010;122(18 Suppl 3):S876-S908. doi:10.1161/CIRCULATIONAHA.110.971101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26868817">
<a name="26868817"></a>Koppen H, Stolwijk J, Wilms EB, van Driel V, Ferrari MD, Haan J. Cardiac monitoring of high-dose verapamil in cluster headache: an international Delphi study. <i>Cephalalgia</i>. 2016;36(14):1385-1388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/26868817/pubmed" id="26868817" target="_blank">26868817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23878619">
<a name="23878619"></a>Koskinas KC, Lillis L, Ziakas A. Diltiazem: a reversible cause of atrioventricular block - until proven otherwise. <i>Open Cardiovasc Med J</i>. 2013;7:46. doi:10.2174/1874192401307010046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/23878619/pubmed" id="23878619" target="_blank">23878619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8804320">
<a name="8804320"></a>Kugler JD, Danford DA. Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. <i>J Pediatr</i>. 1996;129(3):324-338. doi:10.1016/s0022-3476(96)70063-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/8804320/pubmed" id="8804320" target="_blank">8804320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8048248">
<a name="8048248"></a>Kumar KL, Colley CA. Verapamil-induced hepatotoxicity. <i>West J Med</i>. 1994;160(5):485-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/8048248/pubmed" id="8048248" target="_blank">8048248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10746617">
<a name="10746617"></a>Leone M, D'Amico D, Frediani F, et al. Verapamil in the prophylaxis of episodic cluster headache: a double-blind study versus placebo. <i>Neurology</i>. 2000;54(6):1382-1385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/10746617/pubmed" id="10746617" target="_blank">10746617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9590378">
<a name="9590378"></a>Lichtenwalner MR, Mencken T, Tully R, et al. False-positive immunochemical screen for methadone attributable to the metabolites of verapamil. <i>Clin Chem.</i> 1998;44(5):1039-1041.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/9590378/pubmed" id="9590378" target="_blank">9590378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11579867">
<a name="11579867"></a>Maiteh M, Daoud AS. Myoclonic seizure following intravenous verapamil injection: case report and review of the literature. <i>Ann Trop Paediatr</i>. 2001;21(3):271-272. doi:10.1080/02724930120077862<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/11579867/pubmed" id="11579867" target="_blank">11579867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manolis.1">
<a name="Manolis.1"></a>Manolis AS. Premature ventricular complexes: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21986463">
<a name="21986463"></a>Marik PE, Rivera R. Hypertensive emergencies: an update. <i>Curr Opin Crit Care</i>. 2011;17(6):569-580. doi:10.1097/MCC.0b013e32834cd31d.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/21986463/pubmed" id="21986463" target="_blank">21986463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6539877">
<a name="6539877"></a>Markley HG, Cheronis JC, Piepho RW. Verapamil in prophylactic therapy of migraine. <i>Neurology</i>. 1984;34(7):973-976.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/6539877/pubmed" id="6539877" target="_blank">6539877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16987158">
<a name="16987158"></a>May A, Leone M, Afra J, et al; EFNS Task Force. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. <i>Eur J Neurol</i>. 2006;13(10):1066-1077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/16987158/pubmed" id="16987158" target="_blank">16987158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. Key potentially inappropriate drugs in pediatrics: The KIDs list. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3709626">
<a name="3709626"></a>Miller MR, Withers R, Bhamra R, Holt DW. Verapamil and breast-feeding. <i>Eur J Clin Pharmacol</i>. 1986;30(1):125-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/3709626/pubmed" id="3709626" target="_blank">3709626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2915424">
<a name="2915424"></a>Mohindra SK, Udeani GO. Long-acting verapamil and heart failure. <i>JAMA</i>. 1989;261(7):994.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/2915424/pubmed" id="2915424" target="_blank">2915424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4029246">
<a name="4029246"></a>Mooy J, Schols M, v Baak M, Gersh BJ. Pharmacokinetics of verapamil in patients with renal failure. <i>Eir J Clin Pharmacol.</i> 1985;28(4):405-410. doi:10.1007/BF00544358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/4029246/pubmed" id="4029246" target="_blank">4029246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Morgan.1">
<a name="Morgan.1"></a>Morgan JP. Clinical manifestations, diagnosis, and management of the cardiovascular complications of cocaine abuse. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1">
<a name="Nelson.1"></a>National Institute for Health and Care Excellence (NICE). NICE guideline: hypertension in pregnancy: diagnosis and management. http://www.nice.org.uk/guidance/ng133/. Updated June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1">
<a name="Nelson.1"></a>Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neumar.1">
<a name="Neumar.1"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: Adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation.</i> 2010;122(18)(suppl 3):729-767.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25911317">
<a name="25911317"></a>Obermann M, Holle D, Naegel S, Burmeister J, Diener HC. Pharmacotherapy options for cluster headache. <i>Expert Opin Pharmacother</i>. 2015;16(8):1177-1184. doi:10.1517/14656566.2015.1040392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/25911317/pubmed" id="25911317" target="_blank">25911317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33245858">
<a name="33245858"></a>Obermann M, Nägel S, Ose C, et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. <i>Lancet Neurol</i>. 2021;20(1):29-37. doi:10.1016/S1474-4422(20)30363-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/33245858/pubmed" id="33245858" target="_blank">33245858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26409259">
<a name="26409259"></a>Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115. doi:10.1016/j.jacc.2015.08.856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/26409259/pubmed" id="26409259" target="_blank">26409259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult Basic and Advanced Life Support Writing Group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25296862">
<a name="25296862"></a>Patel K, Fonarow GC, Ahmed M, et al. Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction. <i>Circ Heart Fail</i>. 2014;7(6):945-952. doi:10.1161/CIRCHEARTFAILURE.114.001301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/25296862/pubmed" id="25296862" target="_blank">25296862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25172618">
<a name="25172618"></a>Pedersen CT, Kay GN, Kalman J, et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. <i>Europace</i>. 2014;16(9):1257-1283. doi:10.1093/europace/euu194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/25172618/pubmed" id="25172618" target="_blank">25172618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23203776">
<a name="23203776"></a>Pelzer N, Stam AH, Haan J, Ferrari MD, Terwindt GM. Familial and sporadic hemiplegic migraine: diagnosis and treatment. <i>Curr Treat Options Neurol</i>. 2013;15(1):13-27. doi:10.1007/s11940-012-0208-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/23203776/pubmed" id="23203776" target="_blank">23203776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31339562">
<a name="31339562"></a>Petersen AS, Barloese MCJ, Snoer A, Soerensen AMS, Jensen RH. Verapamil and cluster headache: still a mystery. A narrative review of efficacy, mechanisms and perspectives. <i>Headache</i>. 2019;59(8):1198-1211. doi:10.1111/head.13603<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/31339562/pubmed" id="31339562" target="_blank">31339562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9399606">
<a name="9399606"></a>Phillips BG, Gandhi AJ, Sanoski CA, Just VL, Bauman JL. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. <i>Pharmacotherapy</i>. 1997;17(6):1238-1245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/9399606/pubmed" id="9399606" target="_blank">9399606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7725379">
<a name="7725379"></a>Piovan D, Padrini R, Svalato Moreolo G, et al. Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment. <i>Ther Drug Monit.</i> 1995;17(1):60-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/7725379/pubmed" id="7725379" target="_blank">7725379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8339658">
<a name="8339658"></a>Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. <i>Chest</i>. 1993;104(2):618-620. doi:10.1378/chest.104.2.618<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/8339658/pubmed" id="8339658" target="_blank">8339658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22683887">
<a name="22683887"></a>Pringsheim T, Davenport W, Mackie G, et al; Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. <i>Can J Neurol Sci</i>. 2012;39(2)(suppl 2):S1-S59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/22683887/pubmed" id="22683887" target="_blank">22683887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10987906">
<a name="10987906"></a>Razavi M, Razavi B, Fattal D, Afifi A, Adams HP Jr. Hemiplegic migraine induced by exertion. <i>Arch</i>
<i>Neurol</i>. 2000;57(9):1363-1365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/10987906/pubmed" id="10987906" target="_blank">10987906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432623">
<a name="27432623"></a>Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of cluster headache: the American Headache Society evidence-based guidelines. <i>Headache</i>. 2016;56(7):1093-1106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/27432623/pubmed" id="27432623" target="_blank">27432623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi:10.1016/j.jash.2015.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28133614">
<a name="28133614"></a>Roth AD, Lee MY. Idiosyncratic drug-induced liver injury (IDILI): Potential mechanisms and predictive assays. <i>Biomed Res Int</i>. 2017;2017:9176937. doi:10.1155/2017/9176937<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/28133614/pubmed" id="28133614" target="_blank">28133614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31788248">
<a name="31788248"></a>Saedder EA, Thomsen AH, Hasselstrøm JB, Jornil JR. Heart insufficiency after combination of verapamil and metoprolol: A fatal case report and literature review. <i>Clin Case Rep</i>. 2019;7(11):2042-2048. doi:10.1002/ccr3.2393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/31788248/pubmed" id="31788248" target="_blank">31788248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6795914">
<a name="6795914"></a>Sapire DW, O'Riordan AC, Black IF. Safety and efficacy of short- and long-term verapamil therapy in children with tachycardia. <i>Am J Cardiol.</i> 1981;48(6):1091-1097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/6795914/pubmed" id="6795914" target="_blank">6795914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.1">
<a name="Schwedt.1"></a>Schwedt TJ, Garza I. Preventive treatment of episodic migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7243302">
<a name="7243302"></a>Shakibi JG. Arrhythmias in infants and children. <i>Pediatrician.</i> 1981;10(1-3):117-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/7243302/pubmed" id="7243302" target="_blank">7243302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12589171">
<a name="12589171"></a>Sica DA, Gehr TW. Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations. <i>Curr Opin Nephrol Hypertens.</i> 2003;12(2):123-131. doi:10.1097/00041552-200303000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/12589171/pubmed" id="12589171" target="_blank">12589171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-346345">
<a name="346345"></a>Singh BN, Ellrodt G, Peter CT. Verapamil: a review of its pharmacological properties and therapeutic use. <i>Drugs</i>. 1978;15(3):169-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/346345/pubmed" id="346345" target="_blank">346345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6355533">
<a name="6355533"></a>Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. <i>JAMA</i>. 1983;250(18):2500-2502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/6355533/pubmed" id="6355533" target="_blank">6355533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7248141">
<a name="7248141"></a>Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. <i>Br J Clin Pharmacol.</i> 1981;12(1):51-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/7248141/pubmed" id="7248141" target="_blank">7248141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign Against Headache. <i>J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6587753">
<a name="6587753"></a>Storstein L, Larsen A, Midtbo K, et al. Pharmacokinetics of calcium channel blockers in patients with renal insufficiency and in geriatric patients. <i>Acta Med Scand Suppl.</i> 1984;681:25-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/6587753/pubmed" id="6587753" target="_blank">6587753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lifestar.1">
<a name="Lifestar.1"></a>Verapamil injection [prescribing information]. Mahwah, NJ: Lifestar Pharma LLC; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Verapamil injection [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Verelan.1">
<a name="Verelan.1"></a>Verelan (verapamil) [prescribing information]. Princeton, NJ: Kremers Urban; April 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Verelan.2">
<a name="Verelan.2"></a>Verelan (verapamil) extended-release capsules [prescribing information]. Gainesville, GA: Societal CDMO Gainesville LLC; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VerelanPM.1">
<a name="VerelanPM.1"></a>Verelan PM (verapamil) [prescribing information]. Philadelphia, PA: Lannett Company Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12525732">
<a name="12525732"></a>Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. <i>Neurology</i>. 2003;60(1):120-121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/12525732/pubmed" id="12525732" target="_blank">12525732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2045528">
<a name="2045528"></a>Zachariah PK, Moyer TP, Theobald HM, et al. The pharmacokinetics of racemic verapamil in patients with impaired renal function. <i>J Clin Pharmacol</i>. 1991;31(1):45-53. doi:10.1002/j.1552-4604.1991.tb01885.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/2045528/pubmed" id="2045528" target="_blank">2045528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6299085">
<a name="6299085"></a>Zalman F, Perloff JK, Durant NN, Campion DS. Acute respiratory failure following intravenous verapamil in Duchenne's muscular dystrophy. <i>Am Heart J</i>. 1983;105(3):510-511. doi:10.1016/0002-8703(83)90371-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/6299085/pubmed" id="6299085" target="_blank">6299085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234417">
<a name="15234417"></a>Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. <i>J Am Coll Cardiol</i>. 2004;44(1):105-108. doi:10.1016/j.jacc.2004.03.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/verapamil-pediatric-drug-information/abstract-text/15234417/pubmed" id="15234417" target="_blank">15234417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zimetbaum.1">
<a name="Zimetbaum.1"></a>Zimetbaum PJ, Wylie JV. Nonsustained ventricular tachycardia: Clinical manifestations, evaluation, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 25, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12879 Version 681.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
